Besides investments from our main investors, we’ve benefited from collaborations and from grants from TRANSVAC2 (a vaccine project funded by the European Union’s Horizon 2020 research and innovation programme) and the Swiss Innovation Agency, Innosuisse to move our Covid-19 vaccine development forward.